ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1813

Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease

Muhammed Aydin1, Bahar Artim-Esen1, Murat Inanc2, Lale Ocal1 and Ahmet Gül1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Diagnostic criteria, Disease Sub-phenotyping, prognostic factors and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there is no pathognomonic clinical and laboratory finding, diagnosis of BD relies on constellation of a group of manifestations. Recurrent oral aphthous ulcers (ROU) are the commonest manifestation, and widely used classification criteria require ROU in all patients. However, some patients may not have ROU at disease onset, which may cause a challenge and delay in the diagnosis of BD. This study aimed to investigate the disease course and appearance of the manifestations in those patients with or without ROU at the disease onset.

Methods: The study group consisted of 570 patients, who fulfilled the International Study Group (ISG) diagnostic criteria and followed between 1976 and 2016. All patients interviewed personally for their disease course and their medical records were investigated retrospectively. Differences in the disease course were analyzed according to the type of manifestations at the disease onset, sequence of appearance of other manifestations, and their smoking status.

Results: Non-aphthous beginning (NAB) at the disease onset was found in 13.6% of patients, and it was more frequent among smokers compared to non-smokers (18.4% vs 6.8% in males, p=0.019; 22.9% vs 9.7% in females, p=0.038). Frequency of uveitis (54.1% vs 30.2%, p<0.001) and cardiovascular involvement (39.3% vs 24.2%, p=0.019) was higher in patients with NAB compared to the patients with ROU at onset. Both NAB group and ROU at onset group fulfilled the ISG diagnostic criteria within similar disease duration (median 48 vs 54 months). However, a 3-month delay in diagnosis was noted after the fulfillment of ISG criteria in patients with ROU at onset despite a 5.3-month delay in NAB group (p=0.003). Overall, the most frequent manifestations developing at the onset of BD were ROU, genital ulcers, and uveitis; and the latest manifestation during the course was pulmonary parenchymal involvement. Erythema nodosum-like lesions as initial findings were more frequent in females (11.3% vs 5.1%, p=0.024), and deep-vein thrombosis (DVT) was more frequent in males (4.6% vs 0.9%, p=0.04). NAB was identified as an independent risk factor for the development of uveitis (OR=2.06) and DVT (OR= 2.25) by logistic regression analysis. None of the BD patients had arterial aneurysms or thrombosis, pulmonary parenchymal, gastrointestinal or genitourinary involvement as initial manifestations.

Conclusion: This retrospective study revealed that 13.6% of BD patients may not have ROU at the disease onset, and those patients with NAB may have different features in their disease course with a tendency for higher risk of uveitis and DVT. Smoking may also have a role in the increased frequency of NAB in BD patients.


Disclosure: M. Aydin, None; B. Artim-Esen, None; M. Inanc, None; L. Ocal, None; A. Gül, None.

To cite this abstract in AMA style:

Aydin M, Artim-Esen B, Inanc M, Ocal L, Gül A. Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/non-aphthous-beginning-as-an-independent-risk-factor-for-the-course-of-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-aphthous-beginning-as-an-independent-risk-factor-for-the-course-of-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology